Discover this podcast and so much more

Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

Tirzepatide: A New Treatment for Diabetes - Frankly Speaking Ep 285

Tirzepatide: A New Treatment for Diabetes - Frankly Speaking Ep 285

FromFrankly Speaking About Family Medicine


Tirzepatide: A New Treatment for Diabetes - Frankly Speaking Ep 285

FromFrankly Speaking About Family Medicine

ratings:
Length:
11 minutes
Released:
Jul 18, 2022
Format:
Podcast episode

Description

Credits: 0.25 AMA PRA Category 1 Credit™
 
CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-285
Overview: Join us for a closer look at tirzepatide, a first-in-class glucose-dependent insulinotropic peptide (GIP) and a glucagon-like peptide-1 receptor agonist (GLP-1 RA). See how this novel glucose-lowering agent can help raise the bar in both HbA1c lowering and weight loss in patients with type 2 diabetes mellitus.
Episode resource links:
Karagiannis T, Avgerinos I, Liakos A, Del Prato S, Matthews DR, Tsapas A, Bekiari E. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. Diabetologia. 2022 May 17:1–11.

Guest: Alan Ehrlich MD, FAAFP
 
Music Credit: Richard Onorato
Released:
Jul 18, 2022
Format:
Podcast episode

Titles in the series (100)

A weekly Podcast series covering newsworthy topics in primary care medicine.